aacr small banner

We were pleased to have our team present a scientific poster on our preclinical research supporting a MagSense® imaging agent for the detection of ovarian cancer at the AACR Special Conference held in Boston, Massachusettes October 5-7, 2023. Data presented at this meeting is a continuation of the work we presented at the AACR annual meeting earlier this year (April 2023). This additional data enabled us to complete all the proof-of-concept studies of the MagSense folate nanoparticles for ovarian cancer detection and paved the way to advance the program to future IND-enabling studies, ultimately to support a Phase I clinical trial.

Poster Session: 

Poster Title: In Vivo Ovarian Cancer Detection Using Folate Receptor-α Targeted Iron Oxide Nanoparticles.
Poster Session: #B045
Session Date and Time: Friday, October 6, 7:00 p.m.-9:30 p.m.

Request a copy of the poster by providing your info in the form.

Download our AACR Ovarian Cancer 2023 Poster

Provide your information below and you'll be given immediate access to the poster. 

The "Silent Killer"

Ovarian Cancer is often referred to as the “silent killer” because it is largely asymptomatic until late stage and conventional imaging methods are not sensitive enough to detect early and smaller tumors, with only 20-25% of ovarian cancers diagnosed in early stages. However, when ovarian cancer is detected at an early stage (I or II), cytoreductive surgery and conventional chemotherapy can cure 70-90% of patients, compared with approximately 20% of those patients diagnosed at late stage (III and IV).

Reliable detection of ovarian cancer at an earlier stage should significantly improve the type and range of treatment options available to women afflicted with ovarian cancer.

We are developing the MagSense® Ovarian Cancer imaging agent with this in mind.